Developing More Predictive In Vitro Models
3rd Annual Summit
Cutting Edge Advancements in In Vitro Models to Mitigate Toxicity, Streamline Drug Development and Direct Clinical Strategy
25 – 27 September 2012 | Boston
.
Day Two
September 27th, 2012
08.20 Registration, Coffee and Networking
08.50 Chairman’s Opening Remarks
Eric Chiao, Head, Pluripotent Stem Cell Lab, Non-Clincal Safety, Roche
Innovations In 3D Microtissues To Improve Accuracy In Preclinical Models
09.00 Applying a High Throughput Approach to Assay 3D Cell Culture Models of Liver Toxicity
• Creating living, physiological, 3D tissues and organs
• Integrating systems biology and tissue engineering to model liver toxicity in 3D culture
Linda Griffith, Professor, MIT
09.30 Combinatorial Microenvironments: A Continuum of Therapeutic Responses to a Single Pathway
• Much of cancer therapeutic design is conducted in non physiological contexts
• We demonstrate microevironment-dependency of lapatinib response
• Strategy for predicting tissue-specific therapeutic responses
Mark Labarge, Staff Scientist, Lawrence Berkeley National Laboratory
10.00 Heterotypic 3D Culturing Models as Representative Organotypic Models: The Future of Preclinical Drug Development
• Development of an in vitro bone marrow model
• Utility of hollow fiber membrane bioreactors
Mayasari Lim, Assistant Professor, Nanyang Technological University
10.30 Morning Refreshment Break
11.00 In Vitro Models of Blood Vessels as Preclinical Models
• Matching physical properties of tissues in in vitro systems
• Quantifying cell response on biomaterials with tunable properties that mimic disease progression
Joyce Wong, Associate Professor, Boston University
New Developments In Established Models Of Toxicity And Efficacy
11.30 Improvements in Functional In Vitro Systems for Drug Discovery and Development
• Overview of current landscape and future directions in in vitro hepato- and cyto-toxicity prediction
• Identification of biomarkers in in vitro systems that might translate to in vivo
Joe Senn, Lead - Issue Management, Drug Safety Evaluation, Millennium
12.00 Rethinking Mechanism of Action of Predictive Biomarkers
• Case study: Discovering and utilizing preclinical biomarker identification in drug development
• Bridging the gap between the preclinic and the clinic
Arijit Chakravarty, Senior Scientist, Millennium
12.30 Lunch
1.30 Value of Off-Target Mitigation During Early Stage Drug Discovery
• Combining in vitro and in silico data sets for early mitigation of adverse indications
• Therapeutic index considerations and off target safety pharmacology profiling
Laszlo Urban, Global Head, Preclinical Safety Profiling, Novartis
2.00 Interrogative Biology for Identification of Drivers of Biological Systems – Implications for Drug Discovery and Toxicity Assessment
• Data driven inference of causality in normal–disease continuum in integrated multi–omic matrices of biological data
• Rapid identification of biological system drivers - utility in rapid drug discovery, biomarker identification and and predictive functional toxicological assessment
Ranga Sarangarajan, Senior VP and CSO, Berg Pharma
2.30 Afternoon Refreshment Break
3.00 Streamlining Drug Development by Early In Vitro Hepatotoxicity Assessment
• No one assay can predict hepatotoxicity
• Examples of assays that can assist hepatotoxicity assessment and continued improvements to such platforms
Yvonne Will, Senior Principal Scientist, Pfizer
Novel Approaches To Organ Modeling: Lab-On-A-Chip
3.30 Developing Artificial Animal and Human Models to Assess Pharmaceutical Toxicity and Efficacy
• Building experimental models (Body-on-a-Chip) using cell cultures to represent key organs or tissues
• Combining a “Body-on-a-Chip” device and PBPK can quantitatively relate physiological response to the schedule and route of drug(s) applications
• System can be constructed of human and animal cells facilitating cross-species extrapolation
Mike Shuler, Professor, Cornell University
4.00 Novel Platforms for Precise and High Throughput Cell Analysis
• Advantages of miniaturized culture systems for fast and accurate drug screening
• 2.5-dimensional culture systems for accurate representation of various aspects of 3D tissue biology
• Rapid and high-throughput single cell level analysis of molecular networks
Andre Levchenko, Professor, Johns Hopkins University